ArticlePharmacoepidemiology and drug safety2019

Impact of delisting high-strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada.

Diana Martins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.